There is room for additional research to be done on the impact of CB2 agonists on pneumonia-induced acute lung injury as potent agents have been shown to improve the clinical outcome of patients with this disease (Hall et al., 2022). Here, CNR2 is linked to susceptibility to pneumonia measurement.